From: Clinical significance of high monocyte counts for the continuous treatment with nintedanib
Total | With Adverse Event | Without Adverse Event | P-value(univariate) | Odds 95% CI | P-value(multiple) | ||||
---|---|---|---|---|---|---|---|---|---|
(n = 111) | (n = 66) | (n = 45) | |||||||
Age (years) | 70 (66–75) | 70 (66–75.3) | 71 (65–75) | 0.4957 | |||||
Male, n (%) | 80 (72.1) | 50 (75.8) | 30 (66.7) | 0.2968 | |||||
Smoking (pack-years) | 40 (20–57.6) | 40 (20–60) | 40 (19.3–56.8) | 0.6358 | |||||
BMI (kg/m2) | 22.9 (20.6–25.2) | 23.2 (21.3–25.7) | 22.1 (19.7–24.5) | 0.0258 | N/A | ||||
BSA (m2) | 1.62 (1.51–1.72) | 1.63 (1.56–1.73) | 1.56 (1.46–1.69) | 0.0975 | |||||
Albumin | 3.87 (3.59–4.10) | 3.83 (3.52–4.10) | 3.90 (3.61–4.11) | 0.1893 | |||||
C-reactive protein (mg/dL) | 0.28 (0.10–0.59) | 0.28 (0.10–0.77) | 0.28 (0.08–0.50) | 0.0313 | N/A | ||||
KL-6 (U/mL) | 943 (633–1463) | 922 (626–1342) | 993 (645–1694) | 0.4863 | |||||
White blood cell count (x109/L) | 7.400 (6.000–9.700) | 7.550 (6.375–9.725) | 6.800 (5.550–9.725) | 0.5316 | |||||
Monocyte count (x109/L) | 0.451 (0.352–0.600) | 0.492 (0.385–0.630) | 0.410 (0.397–0.557) | 0.0131 | 1.002 (1.005–1.005) | 0.0131 | |||
mMRC score* | 1.62 ± 1.05 | 1.58 ± 0.16 | 1.65 ± 0.13 | 0.7157 | |||||
FVC | 2.18 (1.61–2.86) | 2.18 (1.69–2.89) | 2.25 (1.54–2.85) | 0.8472 | |||||
%FVC | 70.4 (57.1–87.4) | 70.4 (55.4–87.6) | 70.4 (59.3–83.5) | 0.5954 | |||||
%DLco | 56.3 (44.8–73.7) | 55.8 (46.6–71.4) | 61.8 (44.4–76.9) | 0.2675 | |||||
Starting dosage 300 mg (%) | 83 (74.8) | 55 (83.3) | 28 (62.2) | 0.0125 | N/A | ||||
Acute exacerbation | 11(9.9%) | 5(7.6%) | 6(13.3%) | 0.3237 |